
Luminex Corporation EBITDA | LMNX
Earnings before Interest, Taxes, Depreciation, and Amortization (EBITDA), is an often used measure of a company's profitability. Financial analysts use EBITDA for a number of purposes including calculating simple valuations of a firm, estimating cash flows, and assessing debt servicing capability. The uses for EBITDA in financial analysis are numerous, but in practice should be more restrained. While EBITDA has some useful applications, it should be used with caution, as the problems with EBITDA are abundant and can lead to a number of misguided conclusions.[1]
EBITDA is an important indicator for investors and analysts because it allows them to evaluate a company's operating profit without considering the impact of financial expenses, taxes, or non-cash depreciation and amortization. It provides better comparability between companies in different industries or with different tax conditions.
EBITDA is often used to assess a company's ability to generate cash flow and repay debts. It can also serve as a measure of a company's operational efficiency, as it shows how profitable the core business is, regardless of external factors such as interest or taxes.
However, it is important to note that EBITDA is not an official financial statement measure and can be defined and calculated differently by companies. Therefore, investors and analysts should exercise caution when using EBITDA as an evaluation tool and combine it with other financial metrics and information to get a more complete picture of a company's financial condition.
Annual EBITDA Luminex Corporation
| 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|
| 72.9 M | -672 K | 36.5 M | 46 M | 31.5 M | 41.3 M | 33.9 M | 11.3 M | 27 M | 27.2 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 72.9 M | -672 K | 32.7 M |
References
- Brockman, C. M., & Russell, J. W. (2012). EBITDA: use it... or lose it?. International Journal of Business, Accounting and Finance, 6(2), 84-93.
EBITDA of other stocks in the Medical instruments industry
| Issuer | EBITDA | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Atrion Corporation
ATRI
|
37.7 K | - | - | $ 810 M | ||
|
Alcon
ALC
|
1.36 B | $ 67.76 | 0.03 % | $ 33.4 B | ||
|
AngioDynamics
ANGO
|
-17 M | $ 15.68 | 1.1 % | $ 651 M | ||
|
AtriCure
ATRC
|
2.64 M | $ 56.22 | 0.77 % | $ 2.68 B | ||
|
Baxter International
BAX
|
673 M | $ 23.71 | 0.25 % | $ 12.2 B | ||
|
Becton, Dickinson and Company
BDX
|
5.04 B | $ 185.92 | 1.65 % | $ 53.5 B | ||
|
The Cooper Companies
COO
|
1.06 B | $ 53.27 | 0.58 % | $ 10.6 B | ||
|
BioLife Solutions
BLFS
|
-14.3 M | $ 36.39 | 2.71 % | $ 1.74 B | ||
|
electroCore
ECOR
|
-12.7 M | $ 10.05 | 2.97 % | $ 85.3 K | ||
|
Glaukos Corporation
GKOS
|
-162 M | $ 171.68 | 0.34 % | $ 9.82 B | ||
|
Haemonetics Corporation
HAE
|
268 M | $ 106.2 | 0.03 % | $ 5.01 B | ||
|
Harvard Bioscience
HBIO
|
-46.8 M | $ 7.98 | 0.75 % | $ 354 M | ||
|
ICU Medical
ICUI
|
244 M | $ 155.88 | 0.72 % | $ 3.84 B | ||
|
InfuSystem Holdings
INFU
|
25.2 M | $ 12.26 | 0.08 % | $ 253 M | ||
|
iRhythm Technologies
IRTC
|
-36.7 M | $ 111.88 | 2.95 % | $ 3.58 B | ||
|
Intuitive Surgical
ISRG
|
3.55 B | $ 377.16 | 0.01 % | $ 135 B | ||
|
Repro Med Systems
KRMD
|
-2.16 M | $ 3.16 | 0.64 % | $ 146 M | ||
|
LeMaitre Vascular
LMAT
|
78.3 M | $ 80.24 | 0.22 % | $ 1.82 B | ||
|
Microbot Medical
MBOT
|
-14.7 M | $ 1.44 | 0.34 % | $ 65.9 M | ||
|
Milestone Scientific
MLSS
|
-5.62 M | $ 0.4 | 1.42 % | $ 32.8 M | ||
|
Merit Medical Systems
MMSI
|
308 M | $ 86.18 | 0.76 % | $ 5.1 B | ||
|
Nephros
NEPH
|
1.29 M | $ 4.29 | 0.45 % | $ 45.5 M | ||
|
Envista Holdings Corporation
NVST
|
332 M | $ 24.73 | 0.94 % | $ 4.15 B | ||
|
Pro-Dex
PDEX
|
14.4 M | $ 66.91 | 0.53 % | $ 216 B | ||
|
Pulse Biosciences
PLSE
|
-76.5 M | $ 55.2 | 1.83 % | $ 3.72 B | ||
|
ResMed
RMD
|
2.09 B | $ 229.44 | 2.92 % | $ 33.4 B | ||
|
Retractable Technologies
RVP
|
-13.4 M | $ 0.68 | 0.03 % | $ 20.4 M | ||
|
STAAR Surgical Company
STAA
|
-83.4 M | $ 22.45 | 1.81 % | $ 1.11 B | ||
|
STERIS plc
STE
|
1.59 B | $ 210.28 | 1.36 % | $ 20.6 B | ||
|
Teleflex Incorporated
TFX
|
192 M | $ 129.02 | 0.19 % | $ 5.76 B | ||
|
OraSure Technologies
OSUR
|
-61.8 M | $ 3.46 | 2.67 % | $ 254 M | ||
|
Utah Medical Products
UTMD
|
12.2 M | $ 74.63 | 5.6 % | $ 242 M | ||
|
Repligen Corporation
RGEN
|
134 M | $ 174.73 | 4.01 % | $ 9.83 M | ||
|
West Pharmaceutical Services
WST
|
756 M | $ 365.0 | 2.76 % | $ 26.4 B | ||
|
CRH Medical Corporation
CRHM
|
33.9 M | - | - | $ 282 M | ||
|
DENTSPLY SIRONA
XRAY
|
-70 M | $ 9.83 | 0.62 % | $ 1.96 B | ||
|
Stereotaxis
STXS
|
-21.5 M | $ 1.32 | 3.1 % | $ 120 M | ||
|
Cantel Medical Corp.
CMD
|
123 M | - | -1.18 % | $ 3.4 B | ||
|
Akers Biosciences, Inc.
AKER
|
-12.3 M | - | -9.52 % | $ 20.6 M | ||
|
Antares Pharma, Inc.
ATRS
|
16.2 M | - | - | $ 955 M | ||
|
Hill-Rom Holdings, Inc.
HRC
|
518 M | - | -0.05 % | $ 10.3 B | ||
|
Varian Medical Systems, Inc.
VAR
|
60 M | - | -0.02 % | $ 16.3 B | ||
|
NeuroMetrix
NURO
|
-8.69 M | - | 5.05 % | $ 9.02 M | ||
|
Ekso Bionics Holdings
EKSO
|
22.8 M | - | - | $ 28.6 M | ||
|
Isoray
ISR
|
-110 M | - | 0.03 % | $ 108 M | ||
|
Masimo Corporation
MASI
|
-164 M | - | - | $ 9.59 B | ||
|
Predictive Oncology
POAI
|
-181 M | - | - | $ 31.1 M |